Small Graft Size and Hepatocellular Carcinoma Outcomes in Adult-to-Adult Living Donor Liver Transplantation: Multicentric Retrospective Observational Study
Not Applicable
Active, not recruiting
- Conditions
- Neoplasms
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 2500
Inclusion Criteria
Patients with hepatocellular carcinoma who received living donor liver transplants from May 2014 to December 2021.
Exclusion Criteria
1. Age<18
2. Deceased donor liver transplantation
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence of Hepatocellular carcinoma, Death
- Secondary Outcome Measures
Name Time Method Recurrence free survival
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link small graft size to hepatocellular carcinoma recurrence after adult-to-adult living donor liver transplantation?
How does graft size impact survival outcomes in HCC patients undergoing adult-to-adult living donor liver transplantation compared to deceased donor transplants?
Which biomarkers are associated with graft size-related complications in hepatocellular carcinoma liver transplant recipients?
What are the adverse event profiles and management strategies for small graft syndrome in adult liver transplant recipients with HCC?
What are the current therapeutic approaches for hepatocellular carcinoma recurrence prevention in liver transplant recipients with small grafts?